Document Detail

Angiogenic gene therapy: pre-clinical studies and phase I clinical data.
MedLine Citation:
PMID:  11841623     Owner:  NLM     Status:  MEDLINE    
Over the last three decades, significant progress has been made in the management of patients with atherosclerotic coronary and peripheral vascular diseases using medical, surgical, and percutaneous therapies. Despite these advances, there remains a significant population of patients who are not optimal candidates for surgical or percutaneous revascularization. These patients continue to suffer from the debilitating symptoms of their disease and remain at risk for myocardial infarction, limb loss, or death. It was this clinical need, coupled with the advances in the understanding of angiogenesis, that has led to efforts to develop angiogenic therapies for patients with peripheral and myocardial ischemia. In general, these conditions are characterized by local hypovascularity, and the approach to treatment is therefore focused on stimulating neovascularization.
Riyaz Bashir; Peter R Vale; Jeffrey M Isner; Douglas W Losordo
Related Documents :
10933343 - Management of coronary artery disease: therapeutic options in patients with diabetes.
11841623 - Angiogenic gene therapy: pre-clinical studies and phase i clinical data.
1760883 - Serum total free radical trapping ability in acute myocardial infarction.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Kidney international     Volume:  61     ISSN:  1523-1755     ISO Abbreviation:  Kidney Int.     Publication Date:  2002 Jan 
Date Detail:
Created Date:  2002-02-13     Completed Date:  2008-06-03     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0323470     Medline TA:  Kidney Int     Country:  United States    
Other Details:
Languages:  eng     Pagination:  S110-4     Citation Subset:  IM    
Tufts University School of Medicine, Boston, Massachusetts, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angiogenesis Inducing Agents / therapeutic use*
Clinical Trials, Phase I as Topic
Drug Evaluation, Preclinical
Gene Therapy / methods*
Neovascularization, Physiologic / genetics*
Recombinant Proteins / therapeutic use
Vascular Endothelial Growth Factor A / therapeutic use
Reg. No./Substance:
0/Angiogenesis Inducing Agents; 0/Recombinant Proteins; 0/Vascular Endothelial Growth Factor A

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Effects of amino acids and glucose on mesangial cell aminopeptidase a and angiotensin receptors.
Next Document:  Impediments to successful gene transfer to the kidney in the context of transplantation and how to o...